Mr. Garry Nicholson serves as Chairperson of the Board of Topo Therapeutics. He is a seasoned biotechnology leader with extensive experience developing and commercializing innovative therapeutics, and he currently serves on the board of directors for TScan Therapeutics and Avenzo Therapeutics. Earlier in his career, Mr. Nicholson played a key role in the growth and development of numerous companies, including TESARO, Five Prime Therapeutics, Turning Point Therapeutics, Day One Biopharmaceuticals, Tmunity Therapeutics, and G1 Therapeutics, guiding several through successful acquisitions by leading pharmaceutical companies. Prior to that, Mr. Nicholson was President of Pfizer Oncology, where he led global commercialization, sales, clinical development, regulatory strategy, and business development for the company’s oncology portfolio and earlier in his career he held a series of leadership positions within the oncology division of Eli Lilly. Mr. Nicholson received MBA from the University of South Carolina.